Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
Source: SeekingAlpha
2026-02-26 21:28:30 ET
More on Amphastar Pharmaceuticals
- Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
- Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile
- Amphastar Pharmaceuticals Q4 2025 Earnings Preview
- Amphastar reports FDA approval for teriparatide injection
Read the full article on Seeking Alpha
For further details see:
Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
Amphastar Pharmaceuticals Inc.
NASDAQ: AMPH
AMPH Trading
1.41% G/L:
$19.355 Last:
192,512 Volume:
$19.21 Open:
AMPH Latest News
February 26, 2026 04:05:00 pm
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
AMPH Stock Data
$1,321,584,524
33,315,326
0.46%
98
N/A
Pharmaceuticals
Healthcare
US
Rancho Cucamonga
